<unk> , sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis. Side effects include decreased levels of T helper cells, cold sores, allergic reactions and inflammation of the cornea. It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme. It received approval from the United States Food and Drug Administration (FDA) for moderate-to-severe atopic dermatitis in 2017 and for asthma in late 2018. The FDA considers it to be a first-in-class medication.
Dupilumab
Olaratumab
Emapalumab
Ustekinumab
Evolocumab
Burosumab
Sarilumab
Evinacumab